Jesse Anderson Corley Purchases 1,443 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the transaction, the director now owns 1,443 shares of the company’s stock, valued at $44,992.74. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jesse Anderson Corley also recently made the following trade(s):

• On Tuesday, November 12th, Jesse Anderson Corley purchased 11,111 shares of RxSight stock. The shares were purchased at an average price of $45.37 per share, for a total transaction of $504,106.07.

RxSight Trading Down 2.5 %

NASDAQ:RXST opened at $30.39 on Friday. The company’s 50-day moving average price is $38.97 and its 200-day moving average price is $46.70. The company has a market cap of $1.22 billion, a P/E ratio of -36.61 and a beta of 1.20. RxSight, Inc. has a twelve month low of $26.29 and a twelve month high of $66.54.

Hedge Funds Weigh In On RxSight

Hedge funds and other institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC lifted its stake in shares of RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares in the last quarter. Quarry LP increased its position in RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after purchasing an additional 288 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in RxSight during the third quarter worth about $34,000. Quest Partners LLC acquired a new stake in RxSight during the second quarter worth about $41,000. Finally, Harbor Investment Advisory LLC acquired a new stake in RxSight during the fourth quarter worth about $52,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on RXST. Wells Fargo & Company dropped their price target on shares of RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Jefferies Financial Group assumed coverage on shares of RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective on the stock. UBS Group assumed coverage on shares of RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective on the stock. Stifel Nicolaus decreased their price objective on shares of RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a report on Monday, January 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $58.13.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.